Shingo Kajimura, PhD, explained how his curiosity about surviving cold Michigan winters led to the discovery that brown fat is a potent metabolic regulator that can control insulin and glucose levels independent of thermogenesis and independent of the canonical uncoupling protein 1 pathway.
In her award lecture, epidemiologist Juliana C.N. Chan, MBChB, MD, FHKAM, FHKCP, FRCP, detailed her decades of data-driven research and her personal experience working with patients in a major metropolis transformed by global modernization.
Chantal Mathieu, MD, PhD, and other investigators reported on findings from three QWINT studies. Efsitora alfa is now the second long-acting, once-weekly insulin analog that has been evaluated in robust phase 3 studies and proven to be non-inferior to daily insulins.
Rodica Pop-Busui, MD, PhD, and other researchers shared new data showing oral semaglutide improved each of the composite measures of SOUL, death from cardiovascular causes, nonfatal stroke, and nonfatal myocardial infarction.
Katherine R. Tuttle, MD, discussed advancements in the treatment and management of diabetes and chronic kidney disease that have led to a transition from slowing disease progression to maintaining kidney health.
While the diabetes community has yet to reach the ultimate goal of improving health outcomes for every person living with diabetes, great strides have been made. Rita Rastogi Kalyani, MD, MHS, the ADA’s President, Medicine & Science, said the path forward needs to include professional education and advocacy.
Steven E. Kahn, MB, ChB, accepted the Banting Medal for Scientific Achievement on Sunday at the Scientific Sessions. His lab identified a hyperbolic relationship between beta cell response and insulin sensitivity in the early 1990s. In his award lecture, he discussed how this dynamic fits into pathogenesis and progression of type 2 diabetes.
New and revised recommendations for the care of people living with diabetes cover glucose-lowering pharmacotherapy, diabetes, technology, population health considerations, and more. Naushira Pandya, MD, CMD, gave an overview of the updated Standards of Care for older adults with diabetes.
STRIDE principal investigator Subodh Verma, MD, PhD, FRCSC, and others explained how semaglutide can change the trajectory of disease in individuals with type 2 diabetes and peripheral artery disease.
Experts discussed findings from two phase 3 studies that evaluated the efficacy of combined treatment with an amylin analog and a glucagon-like peptide 1 (GLP-1) receptor agonist in inducing weight loss in individuals living with obesity or overweight.